Ionis Pharmaceuticals Inc IONS

Healthcare Biotechnology

Ionis Pharmaceuticals, Inc. is engaged in ribonucleic acid (RNA)-targeted therapeutics. The Company has five marketed medicines and a pipeline in neurology, cardiology, and other areas of high patient need. It has nine medicines in Phase III development and multiple additional medicines in early and mid-stage development. The Company’s products include SPINRAZA, QALSODY, WAINUA, TEGSEDI and WAYLIVRA. SPINRAZA is used for the treatment of patients with spinal muscular atrophy (SMA), a progressive, debilitating and often fatal genetic disease. QALSODY is an antisense medicine that is used for the treatment of adult patients with superoxide dismutase 1 amyotrophic lateral sclerosis (SOD1-ALS), a rare, neurodegenerative disorder that causes progressive loss of motor neurons leading to death. WAINUA is a self-administered subcutaneous LIgand-Conjugated Antisense (LICA) medicine used for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis (ATTRv-PN).

NDAQ:IONS - Post by User

Ionis Pharmaceuticals Inc

Bullboard Posts

Post by bearskoon Feb 25, 2008 3:07pm

644 Views

Post# 14539948

Overview of the stock

Here are some points to consider:

1) Biotech industry is very volatile though ISIS stock prices started accelerating upwards in August and have been smoothly trending up until December.

2) Positive quarterly earnings surprises.

3) Trading Volume has been quite low for the past 5 months - no particular good or bad news.

4) Success in the Biotech industry outweigh recessionary pressures as new patents posses high value in a medical market (which is a basic service)

Since in the past months the stock price has been falling, I suggest to keep watching the headlines for any new information. This company may have something big in store but could possibly just go down with the other

Bullboard Posts

BMO evolves InvestorLine with enhanced tools for options trading